Ten Day Concomitant Therapy Is Superior to Ten Day Sequential Therapy for Helicobacter pylori Eradication.
10.4166/kjg.2014.64.5.260
- Author:
Su Young KIM
1
;
Dong Kyun PARK
;
Kwang An KWON
;
Kyoung Oh KIM
;
Yoon Jae KIM
;
Jun Won CHUNG
Author Information
1. Department of Gastroenterology, Gachon University Gil Medical Center, Incheon, Korea. drgreen@hanmail.net
- Publication Type:Comparative Study ; English Abstract ; Original Article
- Keywords:
Helicobacter pylori;
Eradication;
First-line regimen
- MeSH:
Adult;
Aged;
Amoxicillin/therapeutic use;
Anti-Bacterial Agents/*therapeutic use;
Breath Tests;
Clarithromycin/therapeutic use;
Drug Administration Schedule;
Drug Therapy, Combination;
Female;
Helicobacter Infections/diagnosis/*drug therapy;
*Helicobacter pylori;
Humans;
Lansoprazole/therapeutic use;
Logistic Models;
Male;
Metronidazole/therapeutic use;
Middle Aged;
Proton Pump Inhibitors/*therapeutic use;
Retrospective Studies;
Risk Factors;
Treatment Outcome
- From:The Korean Journal of Gastroenterology
2014;64(5):260-267
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Because the efficacy of standard triple therapy for Helicobacter pylori eradication has declined, new regimens such as sequential therapy (ST) and concomitant therapy (CoCTx) have been introduced. The aim of this study was to compare the efficacy of 10-day ST and 10-day CoCTx for H. pylori eradication. METHODS: We retrospectively reviewed the medical records of 316 patients with proven H. pylori infection. They were assigned to one of 2 regimens; ST (n=191) consisted of, lansoprazole 30 mg and amoxicillin 1 g for 5 days followed by lansoprazole 30 mg, metronidazole 500 mg, and clarithromycin 500 mg for 5 days, and CoCTx (n=125) consisted of lansoprazole 30 mg, amoxicillin 1 g, metronidazole 500 mg, and clarithromycin 500 mg for 10 days. All drugs were administered twice a day. Bacterial eradication was checked by using a 13C-urea breath test at least 4 weeks after completion of treatment. RESULTS: The mean age and male to female ratio was 51.74 and 1.03, respectively. Baseline characteristics were not different in both groups. Ten day CoCTx group (94.4%, 118/125) showed better eradication rate than ST group (82.2%, 157/191) (p=0.002). Drug compliances were not statistically different between the two groups (p=0.19). Side effects were more frequently reported in the CoCTx group than in the ST group (p=0.03). CONCLUSIONS: Ten-day CoCTx was superior to ST in terms of eradicating H. pylori infection. Although the CoCTx producing more side effects than ST, CoCTx can be thought to be a promising alternative to ST as a treatment regimen for H. pylori eradication.
